EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis

  • STATUS
    Recruiting
  • End date
    Jan 4, 2024
  • participants needed
    150
  • sponsor
    Rennes University Hospital
Updated on 26 January 2021
cancer
colectomy
remission
adalimumab
infliximab
steroid therapy
tumor necrosis factor
inflammatory bowel disease
proctocolectomy
vedolizumab
tumor necrosis factor alpha
golimumab
tumour necrosis
proctitis
janus kinase inhibitor
intestinal diseases
pancolitis

Summary

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that results from immune dysregulation. Arguably, the development of Tumor Necrosis Factor (TNF) antagonists (including infliximab, adalimumab and golimumab) revolutionized the management of immune-mediated chronic diseases in the past two decades.

However, about one third of patients will not respond to a first anti-TNF treatment and 10% to 30% will loose response to anti-TNF during the follow-up.

Historically, a switch between anti-TNF was performed to recapture remission and response to anti-TNF. Recently, a new biologic therapy blocking another target has been approved and is now reimbursed during ulcerative colitis, namely vedolizumab. Vedolizumab is an anti-integrin agent avoiding the recruitment of lymphocytes specifically in inflamed gut tissue.

Emerging data suggest that a switch of therapeutic class (meaning a change of biologic target with Non-TNF-targeted biologic) in case of clinical failure or insufficient response to anti-TNF may be the best choice. This idea of a switch out of the anti-TNF class is also supported by data on drug monitoring that may help physician decision making in case of loss of response. However, no trial is currently available and ongoing to assess the best therapeutic strategy. The aim of the proposed study is to assess the best biological based strategy in patient losing response to a first subcutaneous anti-TNF (golimumab and/or adalimumab).

Description

Design :

A prospective, multicenter, randomized, double blind clinical trial

Primary objective :

To determine whether a non-TNF-targeted biologic (vedolizumab) is superior to infliximab to treat patient with UC losing response or with a primary failure to a first subcutaneous anti-TNF drug at week 14.

Secondary objective :

  • To assess the rate of clinical response and remission at Week 54 in each group of treatments and the time to clinical response and remission from baseline ;
  • To assess the changes in faecal calprotectin levels from baseline to week 14 and 54 according to treatment ;
  • To assess the rate of colectomy and hospitalization in each treatment group ;
  • To assess the rate of mucosal healing at week 14 and 54 in each group of treatments ;
  • To assess the rate of loss of response in each group of treatments for patients responder after induction phase ;
  • To assess the changes of quality of life indexes and the disability index from baseline to week 14 and 54 ;
  • To determine the safety profile of each group of treatments ;
  • To characterize the response in each group of treatments according to drug monitoring of the first anti-TNF agent ;
  • To describe the pharmacokinetics of infliximab and vedolizumab as second-line treatment of UC and explore the sources of pharmacokinetic inter-individual variability ;
  • To identify predictive factors of response to the treatment, including pharmacokinetic features

Expected findings and impact:

The patients include in the clinical will not lose any benefit since both treatments are actually indicated and effective in this condition. In both arm of treatment, patients will receive an effective treatment.

The study will optimize physician decision making to decrease the disease activity period in UC patients with known consequence such as hospitalisation, surgery, work cessations with related cost effects.

Details
Condition Ulcerative Colitis, Ulcerative Colitis (Pediatric)
Treatment Infliximab, Vedolizumab Injection
Clinical Study IdentifierNCT03679546
SponsorRennes University Hospital
Last Modified on26 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or non-pregnant female, non-lactating female
years of age or older and less than 75 years
Documented diagnosis of UC for at least 6 months
Left side colitis or pancolitis
Moderate to severe disease according to a Mayo score equal or above 6 with a Mayo endoscopic sub-score of 2 or 3
Active disease despite ongoing treatment with adalimumab or golimumab for at least 12 weeks (inadequate response, failure, loss of response or intolerance)
Ability of the subject to participate fully in all aspects of this clinical trial
Written informed consent must be obtained and documented
Nave to Janus kinase inhibitor (JAK inhibitor)
Affiliation to the national health insurance
Non inclusion Criteria
Contraindication to continue TNF antagonist (ongoing abscess(es), clinical suspicion of tuberculosis, past allergic reaction)
Contraindication to vedolizumab treatment
Steroid treatment > 20 mg/day for at least two weeks before baseline
Proctitis
Stoma
Proctocolectomy or subtotal colectomy
Planned surgery within the year of the trial
Previous exposure to vedolizumab or infliximab
History of cancer during the past 5 years
Pregnancy or breastfeeding
Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty
Ongoing participation to another interventional study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note